Francesca Ferraro, MD, PhD

Acute myeloid leukemia (AML) is a deadly blood cancer that kills most patients within two years of diagnosis. Chemotherapy can put patients into remission, but the majority relapse because residual leukemia cells survive treatment. The immune system has the potential to eliminate these residual cells, but AML actively suppresses immune responses, preventing the body from finishing what chemotherapy started. Dr. Ferraro aims to understand how AML disables immune defenses and to develop strategies that restore them, so that the immune system and chemotherapy can work together to prevent relapse and improve survival. This work is directly relevant to AML and may ultimately inform treatment approaches for other blood cancers as well.